Curated News
By: NewsRamp Editorial Staff
March 23, 2026
Men Avoid Cancer Genetic Tests Despite Higher Risk, Study Finds
TLDR
- Men who undergo genetic cancer testing gain a critical health advantage with 14% positive mutation rates versus 8% for women, enabling proactive risk management.
- Analysis of 224,000 genetic tests shows men represent only 5% of testers despite having higher cancer mortality rates and double the positive mutation likelihood compared to women.
- Increasing male participation in genetic cancer screening could save lives by identifying high-risk individuals earlier, creating a healthier future for families and communities.
- Men are dramatically underrepresented in cancer genetic testing yet face nearly double the mutation detection rates when they do get screened.
Impact - Why it Matters
This news matters because it exposes a dangerous gap in preventive healthcare that directly impacts public health outcomes. Men's reluctance to undergo genetic testing for cancer risks, despite their higher mortality rates and greater likelihood of positive results, means many are missing opportunities for early intervention that could save lives. This disparity not only affects individual health but also strains healthcare systems by allowing preventable cancers to progress to more advanced, costly stages. As companies develop new therapies, increasing screening rates could enhance treatment efficacy and reduce overall cancer burden, making this a critical issue for patients, families, and policymakers to address.
Summary
New research reveals a critical gender disparity in cancer prevention, with men making up just 5% of individuals undergoing genetic testing for inherited cancer risks, despite dying from cancer at higher rates than women. Analysis of over 224,000 tests shows that men who do get screened face significantly higher odds of carrying dangerous genetic mutations, with positive results hitting 14% versus 8% for women. This alarming gap highlights a major public health concern where the group most at risk is the least likely to seek preventive screening.
The news release comes from TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies, which is part of the Dynamic Brand Portfolio at IBN. The platform mentions CNS Pharmaceuticals Inc. (NASDAQ: CNSP) as an example of a company hitting milestones in commercializing novel therapies for various malignancies, connecting the research findings to broader industry developments in cancer treatment. TinyGems provides extensive distribution services, including access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers, positioning itself to amplify such important health news.
This research underscores the urgent need for targeted outreach and education to encourage more men to undergo genetic testing, potentially saving lives through early detection and intervention. The findings are particularly relevant as companies like CNS Pharmaceuticals advance new therapies, making preventive measures even more crucial. For more details, readers can explore the full study and related coverage through the provided links.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Men Avoid Cancer Genetic Tests Despite Higher Risk, Study Finds
